The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.
Menendez criticizes the lack of oversight in the PBM market.
Share & report
More from Bob Menendez
If we do not have a robust trade agenda in the Pacific Island countries that they will not by desire, maybe, but by default ultimately deal with the Chinese.
Without market access I think that we are going to be at a competitive disadvantage with China.
Unless we work with those countries to assimilate those individuals, I do not care what we do at the border, but we will have 25 million feet marching northwards.
For the record, Mr. Secretary, since my time has expired would you respond to that question for me, what are we doing to get the Solomon Islands to be aligned with us, particularly in our security partnership with Australia?
Other voices in this conversation
